---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-051144"
form_type: "8-K"
ticker: "ABVC"
cik: "0001173313"
company_name: "ABVC BIOPHARMA, INC."
filed_at: "2025-06-04T23:59:59+00:00"
generated_at: "2026-05-19T23:39:13.662332+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# ABVC BioPharma shareholders approve all four proposals including related-party land deal

## Summary
- 11 directors re-elected with ~5.9M votes for each; 18,525 withheld per director.
- Simon & Edward, LLP ratified as auditor for FY2025 with 5,903,606 votes for.
- Land purchase from director Shuling Jiang approved (5,832,130 for); may exceed 20% of outstanding shares.
- Equity incentive plan increased to 15% of outstanding shares with annual auto-increase approved (5,691,168 for).
- Quorum of 5,917,309 shares (35.27% voting power) present for annual meeting.

## SEC filing metadata
- accession: 0001213900-25-051144
- form_type: 8-K
- ticker: ABVC
- cik: 0001173313
- company_name: ABVC BIOPHARMA, INC.
- filed_at: 2025-06-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1173313/000121390025051144/0001213900-25-051144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1173313/000121390025051144/ea024460401-8k_abvcbio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-051144
- JSON: https://secwatch.observer/filing/0001213900-25-051144.json
- Plain text: https://secwatch.observer/filing/0001213900-25-051144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.